

# Biagio Ricciuti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2706625/publications.pdf>

Version: 2024-02-01

152  
papers

4,967  
citations

136950

32  
h-index

133252

59  
g-index

157  
all docs

157  
docs citations

157  
times ranked

6694  
citing authors

#	ARTICLE	IF	CITATIONS
1	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. , 2019, 7, 57.		275
2	Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. Journal of Cancer Research and Clinical Oncology, 2019, 145, 479-485.	2.5	253
3	Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-“Small Cell Lung Cancer. JAMA Oncology, 2020, 6, 1952.	7.1	241
4	Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Annals of Oncology, 2019, 30, 1653-1659.	1.2	220
5	Immune Checkpoint Inhibitor Outcomes for Patients With Non-“Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. Journal of Clinical Oncology, 2019, 37, 1927-1934.	1.6	220
6	Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. Journal of Thoracic Oncology, 2022, 17, 399-410.	1.1	151
7	Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. Journal of Clinical Oncology, 2019, 37, 2738-2745.	1.6	138
8	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. Journal of Clinical Oncology, 2020, 38, 576-583.	1.6	135
9	Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. Oncologist, 2019, 24, e327-e337.	3.7	131
10	Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy. Medical Oncology, 2016, 33, 18.	2.5	129
11	Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-“Mutant NSCLC. Clinical Cancer Research, 2020, 26, 2615-2625.	7.0	129
12	Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. Clinical Lung Cancer, 2019, 20, 237-247.e1.	2.6	118
13	Association of High Tumor Mutation Burden in Non-“Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. JAMA Oncology, 2022, 8, 1160.	7.1	117
14	Endothelial and cardiac progenitor cells for cardiovascular repair: A controversial paradigm in cell therapy. , 2018, 181, 156-168.		102
15	Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 4135-4142.	7.0	95
16	Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence. , 2019, 196, 105-116.		88
17	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. European Journal of Cancer, 2020, 128, 17-26.	2.8	85
18	High density lipoprotein cholesterol and cancer: Marker or causative?. Progress in Lipid Research, 2018, 71, 54-69.	11.6	79

#	ARTICLE	IF	CITATIONS
19	Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression $\geq 50\%$ . <i>Annals of Oncology</i> , 2020, 31, 404-411.	1.2	79
20	Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. , 2020, 8, e000678.		78
21	Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). , 2021, 9, e001504.		72
22	Association between Smoking History and Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2021, 81, 2566-2573.	0.9	69
23	Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1177-1187.	4.2	66
24	Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer. <i>Annals of Oncology</i> , 2020, 31, 807-814.	1.2	65
25	Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. , 2019, 7, 87.		60
26	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of $\geq 50\%$ . <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2209-2221.	4.2	60
27	Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	3.0	58
28	ROS1-rearranged Non-Small-Cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS). <i>Clinical Lung Cancer</i> , 2020, 21, 15-20.	2.6	58
29	Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression $\geq 50\%$ : a multicenter study with external validation. , 2020, 8, e001403.		57
30	Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 53-68.	2.5	56
31	Future options for ALK-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 87, 211-219.	2.0	50
32	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020, 21, 498-508.e2.	2.6	50
33	High-Density Lipoprotein Components and Functionality in Cancer: State-of-the-Art. <i>Trends in Endocrinology and Metabolism</i> , 2019, 30, 12-24.	7.1	49
34	SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1176-1187.	1.1	49
35	Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence. <i>Medical Oncology</i> , 2017, 34, 105.	2.5	47
36	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. <i>European Journal of Cancer</i> , 2020, 134, 19-28.	2.8	45

#	ARTICLE	IF	CITATIONS
37	Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer. , 2021, 9, e003536.		45
38	Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 1857-1872.	2.8	41
39	Clinical Outcome With Platinum-Based Chemotherapy in Patients With Advanced Nonsquamous EGFR Wild-Type Non-“Small-Cell Lung Cancer Segregated According to KRAS Mutation Status. Clinical Lung Cancer, 2014, 15, 86-92.	2.6	40
40	&lt;p&gt;Antitumor activity of larotrectinib in tumors harboring &lt;em&gt;NTRK&nbsp;&nbsp;&lt;/em&gt;gene fusions: a short review on the current evidence&lt;/p&gt;. OncoTargets and Therapy, 2019, Volume 12, 3171-3179.	2.0	38
41	Outcomes to first-line pembrolizumab in patients with PD-L1-high (â%¥50%) non-“small cell lung cancer and a poor performance status. , 2020, 8, e001007.		36
42	Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepattis C infection. Lung Cancer, 2020, 145, 181-185.	2.0	36
43	Safety and Efficacy of Nivolumab in Patients With Advanced Non-“small-cell Lung Cancer Treated Beyond Progression. Clinical Lung Cancer, 2019, 20, 178-185.e2.	2.6	35
44	Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition). Translational Lung Cancer Research, 2019, 8, 1163-1173.	2.8	34
45	Enzymes involved in tumor-driven angiogenesis: A valuable target for anticancer therapy. Seminars in Cancer Biology, 2019, 56, 87-99.	9.6	33
46	Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program. Lung Cancer, 2020, 140, 59-64.	2.0	33
47	Non-coding RNAs in lung cancer. Oncoscience, 2014, 1, 674-705.	2.2	33
48	Association between immune-related adverse event timing and treatment outcomes. Oncoimmunology, 2022, 11, 2017162.	4.6	33
49	Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. Annals of Oncology, 2021, 32, 1391-1399.	1.2	32
50	Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy. Therapeutic Advances in Medical Oncology, 2017, 9, 387-404.	3.2	30
51	Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib. Medical Oncology, 2018, 35, 72.	2.5	29
52	Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Na~ve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer. Clinical Drug Investigation, 2016, 36, 683-686.	2.2	27
53	Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer. Journal of the National Cancer Institute, 2021, 113, 1761-1769.	6.3	27
54	Alectinibâ€™s activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series. Journal of Neuro-Oncology, 2016, 129, 355-361.	2.9	25

#	ARTICLE	IF	CITATIONS
55	Large Cell Neuroendocrine Carcinoma Transformation and EGFR -T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1304-1311.	3.0	24
56	Osimertinib. <i>Recent Results in Cancer Research</i> , 2018, 211, 257-276.	1.8	24
57	Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2601-2613.	1.8	22
58	Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661880865.	2.6	22
59	Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes. <i>Clinical and Translational Oncology</i> , 2020, 22, 844-851.	2.4	21
60	Axillary Lymphadenopathy After Coronavirus Disease 2019 Vaccinations in Patients With Thoracic Malignancy: Incidence, Predisposing Factors, and Imaging Characteristics. <i>Journal of Thoracic Oncology</i> , 2021, , .	1.1	21
61	Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD). <i>Translational Lung Cancer Research</i> , 2020, 9, 2428-2439.	2.8	21
62	Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication. <i>Future Oncology</i> , 2020, 16, 1751-1766.	2.4	20
63	Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. <i>Lung Cancer</i> , 2016, 95, 82-87.	2.0	19
64	Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1640-1650.	7.0	19
65	Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications. <i>Medical Oncology</i> , 2018, 35, 4.	2.5	17
66	Antibody-drug conjugates for lung cancer in the era of personalized oncology. <i>Seminars in Cancer Biology</i> , 2021, 69, 268-278.	9.6	17
67	Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?. <i>ESMO Open</i> , 2016, 1, e000022.	4.5	15
68	Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation. <i>Journal of Thoracic Oncology</i> , 2018, 13, e145-e147.	1.1	15
69	Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. <i>Cancer</i> , 2022, 128, 3067-3079.	4.1	15
70	Ductal Breast Carcinoma Metastatic to the Stomach Resembling Primary Linitis Plastica in a Male Patient. <i>Journal of Breast Cancer</i> , 2016, 19, 324.	1.9	14
71	Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors. <i>European Journal of Radiology</i> , 2020, 132, 109275.	2.6	13
72	Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. , 2022, 10, e004374.		13

#	ARTICLE	IF	CITATIONS
73	miRNAs and resistance to EGFR TKIs in EGFR-mutant non-small cell lung cancer: beyond traditional mechanisms of resistance. <i>Ecancermedalscience</i> , 2015, 9, 569.	1.1	12
74	Fatal acute disseminated intravascular coagulation as presentation of advanced ALK -positive non-small cell lung cancer: Does oncogene addiction matter?. <i>Thrombosis Research</i> , 2018, 163, 51-53.	1.7	12
75	Exclusion of patients living with HIV from cancer immune checkpoint inhibitor trials. <i>Scientific Reports</i> , 2021, 11, 6637.	3.3	12
76	A comparison of EGFR mutation status in tissue and plasma cell-free DNA detected by ADx-ARMS in advanced lung adenocarcinoma patients. <i>Translational Lung Cancer Research</i> , 2019, 8, 135-143.	2.8	12
77	Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report. <i>Ecancermedalscience</i> , 2015, 9, 559.	1.1	11
78	Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC. <i>JCO Precision Oncology</i> , 2021, 5, 726-732.	3.0	10
79	Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100074.	1.1	10
80	The safety of nivolumab for the treatment of advanced non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 101-109.	2.4	8
81	Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma. <i>Journal of Thoracic Oncology</i> , 2018, 13, e9-e12.	1.1	8
82	KRAS mutation and DNA repair and synthesis genes in non-small cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2018, 9, 689-696.	1.0	7
83	Long-term responders to PD-1 blockade in patients with advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9549-9549.	1.6	7
84	Effect of STK11 mutations on efficacy of PD-1 inhibition in non-small cell lung cancer (NSCLC) and dependence on KRAS mutation status.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15113-e15113.	1.6	7
85	Malignant Giant Solitary Fibrous Tumor of the Pleura Metastatic to the Thyroid Gland. <i>Tumori</i> , 2016, 102, S16-S21.	1.1	6
86	Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2020, 22, 708-716.	2.4	6
87	Melanosis coli or ischaemic colitis? That is the question. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015212404.	0.5	5
88	Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations. <i>Lung Cancer</i> , 2018, 120, 70-74.	2.0	5
89	Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib. <i>Journal of Thoracic Oncology</i> , 2018, 13, e220-e222.	1.1	5
90	Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, S1831-S1834.	1.4	5

#	ARTICLE	IF	CITATIONS
91	What Is the Standard First-Line Treatment for Advanced Non-Small Cell Lung Cancer?. Cancer Journal (Sudbury, Mass ), 2020, 26, 485-495.	2.0	5
92	Higher TLR7 Gene Expression Predicts Poor Clinical Outcome in Advanced NSCLC Patients Treated with Immunotherapy. Genes, 2021, 12, 992.	2.4	5
93	MA10.06 Impact of Immune-Related Adverse Events on Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab. Journal of Thoracic Oncology, 2018, 13, S390-S391.	1.1	4
94	MA09.11 Mechanisms of Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14 Mutant Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, S285.	1.1	4
95	Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. JCO Precision Oncology, 2021, 5, 501-509.	3.0	4
96	Chemo-immunotherapy outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer.. Journal of Clinical Oncology, 2021, 39, 9088-9088.	1.6	4
97	Association of a very high tumor mutational load with increased CD8+ and PD-1+ T-cell infiltration and improved clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels in non-small cell lung cancer.. Journal of Clinical Oncology, 2021, 39, 9018-9018.	1.6	4
98	Impact of KRAS allele subtypes and concurrent genomic alterations on clinical outcomes to programmed death 1 axis blockade in non-small cell lung cancer.. Journal of Clinical Oncology, 2019, 37, 9082-9082.	1.6	4
99	Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score $\geq 90\%$ .. Journal of Clinical Oncology, 2019, 37, 9111-9111.	1.6	4
100	Early plasma circulating tumor DNA (ctDNA) changes to predict response to first-line pembrolizumab +/- chemotherapy in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, 3518-3518.	1.6	4
101	Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a Patient With MET Exon 14-Mutant NSCLC. JTO Clinical and Research Reports, 2020, 1, 100072.	1.1	4
102	Artificial intelligence in digital pathology approach identifies the predictive impact of tertiary lymphoid structures with immune-checkpoints therapy in NSCLC.. Journal of Clinical Oncology, 2022, 40, 9065-9065.	1.6	4
103	Clinical outcome of platinum/etoposide treated large cell neuroendocrine carcinomas of the lung according to the type of radiotherapy received: a single institution analysis. Annals of Oncology, 2015, 26, vi78.	1.2	3
104	Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient. Journal of Thoracic Oncology, 2017, 12, e51-e55.	1.1	3
105	MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC. Journal of Thoracic Oncology, 2019, 14, S294-S295.	1.1	3
106	Three-year outcomes and correlative analyses in patients with non-small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) $\geq 90\%$ treated with first-line pembrolizumab.. Journal of Clinical Oncology, 2022, 40, 9043-9043.	1.6	3
107	First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC. Translational Lung Cancer Research, 2018, 7, S127-S130.	2.8	2
108	Emerging Biomarkers in the Era of Personalized Cancer Medicine. Disease Markers, 2019, 2019, 1-2.	1.3	2



#	ARTICLE	IF	CITATIONS
109	Osimertinib for EGFR-mutant non-small cell lung cancer: place in therapy and future perspectives. <i>Journal of Thoracic Disease</i> , 2019, 11, S249-S252.	1.4	2
110	OA03.07 Immune-Related Adverse Events and Clinical Outcome to Anti PD-1 Axis Inhibition in SCLC: A Multicenter Retrospective Analysis. <i>Journal of Thoracic Oncology</i> , 2019, 14, S213-S214.	1.1	2
111	P2.04-32 Comparison of Clinicopathological and Genomic Characteristics Between NSCLCs with a PD-L1 Tumor Proportion Score of $\geq 90\%$ vs $< 1\%$ . <i>Journal of Thoracic Oncology</i> , 2019, 14, S720-S721.	1.1	2
112	Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib. <i>Clinical Lung Cancer</i> , 2020, 21, e478-e487.	2.6	2
113	DNMT3A mutation to identify a subset of non-small cell lung cancers with increased sensitivity to PD-(L)1 blockade.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9113-9113.	1.6	2
114	Clinicopathologic and genomic correlates of tumor-infiltrating immune cells and immunotherapy efficacy in NSCLC.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9121-9121.	1.6	2
115	Immune-related adverse events to predict survival in patients with advanced non-small cell lung cancer treated with nivolumab: A multicenter analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9084-9084.	1.6	2
116	Immune-mediated colitis after resumption of immune checkpoint inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2577-2577.	1.6	2
117	DNA damage response gene alterations are associated with high tumor mutational burden and clinical benefit from programmed death 1 axis inhibition in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9077-9077.	1.6	2
118	Clinicopathologic characteristics and immunotherapy outcomes in SMARCA4-mutant (mut) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9577-9577.	1.6	2
119	Targeting EGFR and ALK in NSCLC: current evidence and future perspective. <i>Lung Cancer Management</i> , 2016, 5, 79-90.	1.5	1
120	Therapeutic approach to brain metastasis in high-grade neuroendocrine carcinomas of the lung: where do we stand?. <i>Journal of Radiation Oncology</i> , 2017, 6, 11-19.	0.7	1
121	Immune-related adverse events correlate with clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with nivolumab in the Italian expanded access programme. <i>Annals of Oncology</i> , 2018, 29, x18-x19.	1.2	1
122	Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option. <i>Translational Lung Cancer Research</i> , 2019, 8, S378-S382.	2.8	1
123	775 Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2019, 114, S450-S451.	0.4	1
124	Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. , 2020, 69, 1177.		1
125	Double aortic arch with right positioned descending thoracic aorta and coexistent aortic kinking. <i>BMJ Case Reports</i> , 2015, 2015, .	0.5	1
126	Immune pneumonitis-related treatment discontinuations and outcomes in metastatic non-small cell lung cancer treated with nivolumab: A pooled analysis from a multi-institutional international collaboration.. <i>Journal of Clinical Oncology</i> , 2019, 37, 118-118.	1.6	1



#	ARTICLE	IF	CITATIONS
127	Clinical characteristics, genomic features, and recurrence risk of early-stage MET exon 14 mutant non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, 9042-9042.	1.6	1
128	Immune gene expression and bayesian network analysis in advanced non small cell lung cancer (NSCLC) patients treated with immunotherapy.. Journal of Clinical Oncology, 2019, 37, e20693-e20693.	1.6	1
129	Reply to Cortellini A. JTO Clinical and Research Reports, 2020, 1, 100095.	1.1	1
130	Genomic correlates of acquired resistance to PD-(L)1 blockade in patients with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2022, 40, 9021-9021.	1.6	1
131	Distinct genomic and immunophenotypic features of solid-predominant versus nonsolid-predominant stage I lung adenocarcinomas and association with disease recurrence after surgical resection.. Journal of Clinical Oncology, 2022, 40, 8514-8514.	1.6	1
132	Activating MET kinase domain mutations define a novel molecular subtype of non-“small cell lung cancer that is clinically targetable with the MET inhibitor elzovantinib (TPX-0022).. Journal of Clinical Oncology, 2022, 40, 9124-9124.	1.6	1
133	Digital quantification of lymphocytic infiltration on routine H&E images and immunotherapy response in non-“small cell lung cancer.. Journal of Clinical Oncology, 2022, 40, 9066-9066.	1.6	1
134	Differential prognostic effect of systemic inflammation in patients with NSCLC treated with immunotherapy or chemotherapy: A post hoc analysis of the phase III OAK trial.. Journal of Clinical Oncology, 2022, 40, 9056-9056.	1.6	1
135	Efficacy of platinum-based chemotherapy in EGFR WT nonsquamous advanced non-small cell lung cancer (NSCLC) patients: association with KRAS mutation and thymidylate synthase (TS) levels. Annals of Oncology, 2017, 28, vi58-vi59.	1.2	0
136	P1.01-15 ROS1-Rearranged Non-Small Cell Lung Cancer Is Associated with High Rate of Venous Thromboembolism: Analysis of The METROS Trial. Journal of Thoracic Oncology, 2018, 13, S464-S465.	1.1	0
137	P1.15-01 Radiotherapy (RT) and Nivolumab in Non-Small-Cell Lung Cancer (NSCLC): A Multicenter Real-Life Experience. Journal of Thoracic Oncology, 2018, 13, S611.	1.1	0
138	Reply to J. Delyon et al. Journal of Clinical Oncology, 2019, 37, 3564-3565.	1.6	0
139	P1.04-04 DNA Damage Response Gene Alterations Are Associated with High Tumor Mutational Burden and Clinical Benefit from PD-1 Axis Inhibition in NSCLC. Journal of Thoracic Oncology, 2019, 14, S439-S440.	1.1	0
140	P1.01-65 Immune Gene Expression, Bayesian Network and Genetic Mutation Analysis in Advanced NSCLC Patients Treated with Immunotherapy. Journal of Thoracic Oncology, 2019, 14, S384-S385.	1.1	0
141	Clinicopathologic, genomic, and tumor microenvironment correlates of aneuploidy and immunotherapy outcomes in NSCLC.. Journal of Clinical Oncology, 2021, 39, 9119-9119.	1.6	0
142	Changes in PD-L1 tumor proportion score are associated with <i>CD274</i> gene (encoding PD-L1) copy number variation in non-small cell lung cancer.. Journal of Clinical Oncology, 2021, 39, 9029-9029.	1.6	0
143	Response to Hopkins, Kichenadasse, Logan, et al. Journal of the National Cancer Institute, 2021, , .	6.3	0
144	Systemic effect of radiotherapy (RT) followed by programmed death 1 (PD-1) inhibitors in non-small-cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2018, 36, 177-177.	1.6	0

#	ARTICLE	IF	CITATIONS
145	Updated outcomes of previously irradiated non-small-cell lung cancer (NSCLC) patients (pts) receiving programmed death 1 (PD-1) inhibitors.. Journal of Clinical Oncology, 2018, 36, e15158-e15158.	1.6	0
146	Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small-cell lung cancer and a poor performance status.. Journal of Clinical Oncology, 2020, 38, 9568-9568.	1.6	0
147	Influence of antibiotic therapy (ATB) on oncological outcomes of metastatic non-small cell lung cancer (mNSCLC) patients treated with chemo-immunotherapy (CIT).. Journal of Clinical Oncology, 2020, 38, 3080-3080.	1.6	0
148	Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities. Tumori, 2022, , 030089162110694.	1.1	0
149	Outcomes of single-agent PD-(L)-1 versus combination with chemotherapy in patients with PD-L1-high (≥50%) non-small cell lung cancer.. Journal of Clinical Oncology, 2022, 40, 9054-9054.	1.6	0
150	Immunophenotypic correlates and response to first-line pembrolizumab among elderly patients with PD-L1-high (≥50%) non-small cell lung cancer.. Journal of Clinical Oncology, 2022, 40, 9054-9054.	1.6	0
151	Impact of <i>STK11</i> copy loss on clinical outcomes to PD-(L)1 blockade in non-small cell lung cancer.. Journal of Clinical Oncology, 2022, 40, 9059-9059.	1.6	0
152	Clinical characteristics and molecular features of non-small cell lung cancers (NSCLCs) following disease progression on immune checkpoint inhibitors (ICIs).. Journal of Clinical Oncology, 2022, 40, e21178-e21178.	1.6	0